迈博药业-B(02181)：张雁云已获指定为首席独立非执行董事

Core Viewpoint - The announcement details changes in the board composition of Maibo Pharmaceutical-B (02181), effective from October 31, 2025, including new appointments and resignations within the nomination committee [1] Group 1 - Dr. Qian Weizhu has been appointed as a member of the company's nomination committee [1] - Mr. Tao Jing will no longer serve as a member of the nomination committee [1] - Dr. Zhang Yanyun, an independent non-executive director and chairman of the remuneration committee, has been designated as the chief independent non-executive director [1]